These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
820 related articles for article (PubMed ID: 23827160)
1. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387. Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160 [TBL] [Abstract][Full Text] [Related]
2. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2). Kort A; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH Pharmacol Res; 2015 Dec; 102():200-7. PubMed ID: 26361725 [TBL] [Abstract][Full Text] [Related]
3. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice. Zhou L; Schmidt K; Nelson FR; Zelesky V; Troutman MD; Feng B Drug Metab Dispos; 2009 May; 37(5):946-55. PubMed ID: 19225039 [TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. de Vries NA; Zhao J; Kroon E; Buckle T; Beijnen JH; van Tellingen O Clin Cancer Res; 2007 Nov; 13(21):6440-9. PubMed ID: 17975156 [TBL] [Abstract][Full Text] [Related]
5. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939 [TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. Chen Y; Agarwal S; Shaik NM; Chen C; Yang Z; Elmquist WF J Pharmacol Exp Ther; 2009 Sep; 330(3):956-63. PubMed ID: 19491323 [TBL] [Abstract][Full Text] [Related]
7. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Marchetti S; de Vries NA; Buckle T; Bolijn MJ; van Eijndhoven MA; Beijnen JH; Mazzanti R; van Tellingen O; Schellens JH Mol Cancer Ther; 2008 Aug; 7(8):2280-7. PubMed ID: 18723475 [TBL] [Abstract][Full Text] [Related]
8. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Breedveld P; Pluim D; Cipriani G; Wielinga P; van Tellingen O; Schinkel AH; Schellens JH Cancer Res; 2005 Apr; 65(7):2577-82. PubMed ID: 15805252 [TBL] [Abstract][Full Text] [Related]
9. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH Mol Pharm; 2012 Nov; 9(11):3236-45. PubMed ID: 23020847 [TBL] [Abstract][Full Text] [Related]
10. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Tang SC; Nguyen LN; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH Int J Cancer; 2014 Mar; 134(6):1484-94. PubMed ID: 24037730 [TBL] [Abstract][Full Text] [Related]
11. Role of P-glycoprotein on the brain penetration and brain pharmacodynamic activity of the MEK inhibitor cobimetinib. Choo EF; Ly J; Chan J; Shahidi-Latham SK; Messick K; Plise E; Quiason CM; Yang L Mol Pharm; 2014 Nov; 11(11):4199-207. PubMed ID: 25243894 [TBL] [Abstract][Full Text] [Related]
12. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation. van Hoppe S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH Pharmacol Res; 2017 Jun; 120():43-50. PubMed ID: 28288939 [TBL] [Abstract][Full Text] [Related]
13. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib. Graber-Maier A; Gutmann H; Drewe J Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289 [TBL] [Abstract][Full Text] [Related]
14. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699). Durmus S; Sparidans RW; van Esch A; Wagenaar E; Beijnen JH; Schinkel AH Pharm Res; 2015 Jan; 32(1):37-46. PubMed ID: 24962512 [TBL] [Abstract][Full Text] [Related]
15. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate. Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030 [TBL] [Abstract][Full Text] [Related]
16. Bcrp1;Mdr1a/b;Mrp2 combination knockout mice: altered disposition of the dietary carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) and its genotoxic metabolites. Vlaming ML; Teunissen SF; van de Steeg E; van Esch A; Wagenaar E; Brunsveld L; de Greef TF; Rosing H; Schellens JH; Beijnen JH; Schinkel AH Mol Pharmacol; 2014 Mar; 85(3):520-30. PubMed ID: 24334255 [TBL] [Abstract][Full Text] [Related]
17. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Allen JD; Van Dort SC; Buitelaar M; van Tellingen O; Schinkel AH Cancer Res; 2003 Mar; 63(6):1339-44. PubMed ID: 12649196 [TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210 [TBL] [Abstract][Full Text] [Related]
19. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier. Bihorel S; Camenisch G; Lemaire M; Scherrmann JM J Neurochem; 2007 Sep; 102(6):1749-1757. PubMed ID: 17696988 [TBL] [Abstract][Full Text] [Related]
20. The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2). Römermann K; Helmer R; Löscher W Neuropharmacology; 2015 Jun; 93():7-14. PubMed ID: 25645391 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]